FENNEC PHARMACEUTICALS INC.

Fennec Pharmaceuticals Inc. (Nasdaq Capital Market) is a commercial-stage specialty pharmaceutical company dedicated to preventing cisplatin-induced ototoxicity, a serious and often irreversible side effect of cancer treatment in pediatric patients. The company's website is www.fennecpharma.com.

The company's primary product is PEDMARK® (sodium thiosulfate injection), the first and only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. PEDMARK® received FDA approval in September 2022 and became commercially available in the United States in October 2022. In Europe, the product is branded as PEDMARQSI® and received European Commission Marketing Authorization in June 2023, with United Kingdom approval following in October 2023.

Clinical studies demonstrated that PEDMARK® treatment resulted in approximately 50 percent relative reduction in the incidence of cisplatin-induced hearing loss compared to cisplatin alone, without evidence of materially compromised antitumor efficacy. The company estimates approximately 2,157 cisplatin-treated pediatric patients in the United States and 1,250 in Europe annually fall within the current PEDMARK® market. In the United States, approximately 90 percent of pediatric cancer patients receive care at approximately 200 key pediatric hospital centers.

Fennec has established strategic partnerships for international commercialization. In March 2024, the company entered into an exclusive licensing agreement with Norgine, a leading European specialist pharmaceutical company, for commercialization of PEDMARQSI® in Europe, Australia, and New Zealand. Fennec received approximately 43 million dollars in upfront consideration and may receive up to approximately 230 million dollars in additional commercial and regulatory milestone payments plus tiered royalties on net sales. In 2025, the company entered into a distribution agreement with Inpharmus for commercialization in Turkey and Gulf Cooperation Council countries.

The company holds orphan drug exclusivity for PEDMARK® in the United States, providing seven years of market exclusivity from FDA approval through September 2029. Fennec maintains six patents listed in the FDA Orange Book covering PEDMARK® formulation and methods of use, with expiration dates in 2039. The company operates as a virtual drug manufacturer, relying on contract manufacturers and suppliers for production and distribution of PEDMARK®.